Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
http://ir.librarynmu.com/handle/123456789/20448Повний запис метаданих
| Поле DC | Значення | Мова |
|---|---|---|
| dc.contributor.author | Kostiuk, I. | - |
| dc.contributor.author | Polova, Z. | - |
| dc.contributor.author | Kosyachenko, K. | - |
| dc.contributor.author | Savchenko, D. | - |
| dc.date.accessioned | 2026-11-02T09:32:51Z | - |
| dc.date.available | 2026-11-02T09:32:51Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | Kostiuk, I., Polova, Z., Kosyachenko, K., Savchenko, D. (2026). Implementation of the managed entry agreement framework in Ukraine: a national analysis of the pathway from health technology assessment to concluded agreements. ScienceRise: Pharmaceutical Science, 5 (63), 31–38. https:// doi.org/10.15587/2519-4852.2026.378478 | uk_UA |
| dc.identifier.issn | UDC 615.12:614.2:339.13 | - |
| dc.identifier.issn | DOI: 10.15587/2519-4852.2026.378478 | - |
| dc.identifier.uri | http://ir.librarynmu.com/handle/123456789/20448 | - |
| dc.description.abstract | The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics.The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics. | uk_UA |
| dc.language.iso | en | uk_UA |
| dc.publisher | ScienceRise: Pharmaceutical Science № 5(63)2026 | uk_UA |
| dc.subject | managed entry agreements, health technology assessment, innovative medicines, public procurement, pharmaceutical policy, access to medicines, reimbursement, negotiation process, pharmaceutical companies, Ukraine | uk_UA |
| dc.title | Implementation Of The Managed Entry Agreement Framework In Ukraine: A National Analysis Of The Pathway From Health Technology Assessment To Concluded Agreements | uk_UA |
| dc.title.alternative | IMPLEMENTATION OF THE MANAGED ENTRY AGREEMENT FRAMEWORK IN UKRAINE: A NATIONAL ANALYSIS OF THE PATHWAY FROM HEALTH TECHNOLOGY ASSESSMENT TO CONCLUDED AGREEMENTS | uk_UA |
| dc.type | Article | uk_UA |
| Розташовується у зібраннях: | Наукові публікації кафедри організації та економіки фармації | |
Файли цього матеріалу:
| Файл | Опис | Розмір | Формат | |
|---|---|---|---|---|
| Implementation Of The Managed Entry Agreement Framework In Ukraine.pdf | 916,07 kB | Adobe PDF | Переглянути/Відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.